Intercept Pharmaceuticals Upgraded by Nomura to “Buy” (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities research analysts at Nomura from a “neutral” rating to a “buy” rating in a research note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm currently has a $323.00 target price on the stock. Nomura’s price objective would indicate a potential upside of 34.28% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 14th. They set a “buy” rating and a $395.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock. Finally, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, June 30th. They set an “outperform” rating and a $425.00 price target on the stock. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $454.20.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 240.55 on Tuesday. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock’s 50-day moving average is $244.0 and its 200-day moving average is $296.. The company’s market cap is $5.072 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.